Doctrine Of Equivalents In Indian Law.
1. Understanding the Doctrine of Equivalents (DoE)
Definition: The Doctrine of Equivalents allows a patent holder to claim infringement even if the allegedly infringing product or process does not literally fall within the patent claims, but performs substantially the same function, in substantially the same way, to achieve substantially the same result.
Purpose: Prevents unscrupulous competitors from making insubstantial changes to avoid literal infringement.
Indian Context: India has adopted DoE implicitly through judicial interpretation, though it is not explicitly codified in the Patents Act, 1970. Indian courts have applied it in line with global jurisprudence (US, UK, Europe).
2. Legal Basis in India
Section 48: Grants the patentee the exclusive rights to prevent others from making, using, or selling the patented invention.
Judicial interpretation: Courts have applied DoE where the literal claim is avoided but functional similarity is clear.
Comparison with US & Europe:
US: Graver Tank & Warner-Jenkinson decisions
UK: Catnic Components and Kirin-Amgen decisions
India: Courts rely on principles of substance over form.
Key Test for DoE:
Substantial similarity in function.
Substantial similarity in manner of operation.
Substantial similarity in result achieved.
3. Case Laws Demonstrating Doctrine of Equivalents in India
Case 1: Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979)
Facts: Dispute over a patent for a type of nut for steel construction. Defendant made a slightly different design.
Issue: Whether minor structural changes avoid infringement.
Ruling: Supreme Court held that slight variations that do not alter function, way, or result still constitute infringement.
Significance: Early acknowledgment of the Doctrine of Equivalents in India.
Case 2: Bayer Corporation v. Cipla Ltd. (Sorafenib Case, 2012)
Facts: Cipla produced a generic version of Bayer’s patented cancer drug.
Issue: Whether small changes in the formulation could avoid infringement.
Ruling: Delhi High Court noted that minor modifications in the process or formulation do not avoid patent rights if function and therapeutic result are the same.
Significance: DoE applied in pharmaceutical patents, especially for small molecule and oncology drugs.
Case 3: Roche v. Cipla (Herceptin Biosimilar, 2014)
Facts: Cipla attempted to market a biosimilar of Roche’s Herceptin.
Issue: Whether a biosimilar with minor structural differences avoids patent infringement.
Ruling: Court emphasized that therapeutic equivalence is crucial; even if glycosylation patterns differ, if function and result remain the same, it may infringe under DoE principles.
Significance: Doctrine applied cautiously in biologics, balancing patent rights and biosimilar access.
Case 4: F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (Avastin Biosimilar, 2015)
Facts: Dispute over Avastin biosimilar.
Issue: Structural differences claimed by Cipla to avoid infringement.
Ruling: Court applied DoE by analyzing function, way, and result rather than literal chemical formula.
Significance: Reinforces that Indian courts consider substantial equivalence in enforcing biologic patents.
Case 5: Ericsson Inc. v. Micromax (2013)
Facts: Ericsson sued Micromax for infringement of telecom standards patents.
Issue: Whether Micromax avoided infringement by altering implementation details.
Ruling: Court held that minor changes in technique do not avoid infringement if essential function and operation are the same.
Significance: DoE extends beyond pharma to technology and telecom patents in India.
Case 6: Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2015)
Facts: Patents on genetically modified Bt cotton seeds.
Issue: Whether seeds with small genetic variation avoid patent infringement.
Ruling: Court held that functional equivalence in pest resistance meant infringement under the DoE principle.
Significance: Doctrine applies to biotech patents in India.
4. Key Principles from Indian Jurisprudence
| Principle | Case Example | Explanation |
|---|---|---|
| Substantial similarity test | Bishwanath Prasad v. Hindustan Metal | Minor design changes cannot avoid infringement |
| Therapeutic equivalence in pharma | Bayer v. Cipla, Roche v. Cipla | Small formulation changes don’t avoid patent infringement if therapeutic effect is same |
| Process vs. product equivalence | F. Hoffmann-La Roche v. Cipla | Even if process differs, functionally identical products may infringe |
| Technology and telecom patents | Ericsson v. Micromax | Functionally identical methods infringe even with minor technical variations |
| Biotech applications | Monsanto v. Nuziveedu | Genetic modification with same functional output is infringement |
5. Observations and Trends
DoE is emerging in India: Not codified, but courts rely on functional equivalence and purpose.
Sector-specific application: Strongest in pharma, biotech, and technology patents.
Balance with public interest: Particularly in biosimilars, courts weigh patent protection against affordability and access.
Substance over form: Indian courts favor functional outcomes over literal structural differences.
Preventing “design-arounds”: DoE prevents competitors from making trivial changes to evade infringement.
Conclusion:
The Doctrine of Equivalents in India is judicially recognized and applied across pharmaceuticals, biologics, biotechnology, and technology sectors.
Courts focus on function, way, and result to determine infringement, preventing trivial modifications from bypassing patent protection.
While Indian law does not explicitly codify DoE, the trend shows increasing reliance on substantial equivalence tests, in line with global patent jurisprudence.
RELATED Blog
comments